GOSS Quote, Financials, Valuation and Earnings

Palatin Technologies has a net margin of -362.73% compared to Gossamer Bio, Inc.'s net margin of --. Gossamer Bio, Inc.'s return on equity of -615% beat Palatin Technologies's return on equity of --.

Gossamer Bio, Inc. has a consensus price target of $9.50, signalling upside risk potential of 194.12%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Gossamer Bio, Inc., analysts believe Palatin Technologies is more attractive than Gossamer Bio, Inc..

Gossamer Bio, Inc. has a beta of 1.921, which suggesting that the stock is 92.071% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Gossamer Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gossamer Bio, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Gossamer Bio, Inc. quarterly revenues are $13.3M, which are larger than Palatin Technologies quarterly revenues of --. Gossamer Bio, Inc.'s net income of -$48.2M is higher than Palatin Technologies's net income of --. Notably, Gossamer Bio, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gossamer Bio, Inc. is 16.66x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Rezolute, Inc. has a net margin of -362.73% compared to Gossamer Bio, Inc.'s net margin of --. Gossamer Bio, Inc.'s return on equity of -615% beat Rezolute, Inc.'s return on equity of -63.8%.

Gossamer Bio, Inc. has a consensus price target of $9.50, signalling upside risk potential of 194.12%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.13 which suggests that it could grow by 54.49%. Given that Gossamer Bio, Inc. has higher upside potential than Rezolute, Inc., analysts believe Gossamer Bio, Inc. is more attractive than Rezolute, Inc..

Gossamer Bio, Inc. has a beta of 1.921, which suggesting that the stock is 92.071% more volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.211, suggesting its less volatile than the S&P 500 by 78.913%.

Gossamer Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gossamer Bio, Inc. pays -- of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend.

Gossamer Bio, Inc. quarterly revenues are $13.3M, which are larger than Rezolute, Inc. quarterly revenues of --. Gossamer Bio, Inc.'s net income of -$48.2M is lower than Rezolute, Inc.'s net income of -$18.2M. Notably, Gossamer Bio, Inc.'s price-to-earnings ratio is -- while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gossamer Bio, Inc. is 16.66x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -362.73% compared to Gossamer Bio, Inc.'s net margin of --. Gossamer Bio, Inc.'s return on equity of -615% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Gossamer Bio, Inc. has a consensus price target of $9.50, signalling upside risk potential of 194.12%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3559.17%. Given that Theriva Biologics, Inc. has higher upside potential than Gossamer Bio, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Gossamer Bio, Inc..

Gossamer Bio, Inc. has a beta of 1.921, which suggesting that the stock is 92.071% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Gossamer Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Gossamer Bio, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Gossamer Bio, Inc. quarterly revenues are $13.3M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Gossamer Bio, Inc.'s net income of -$48.2M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Gossamer Bio, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gossamer Bio, Inc. is 16.66x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -362.73% compared to Gossamer Bio, Inc.'s net margin of 52.48%. Gossamer Bio, Inc.'s return on equity of -615% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Gossamer Bio, Inc. has a consensus price target of $9.50, signalling upside risk potential of 194.12%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 147.51%. Given that Gossamer Bio, Inc. has higher upside potential than XOMA Royalty Corp., analysts believe Gossamer Bio, Inc. is more attractive than XOMA Royalty Corp..

Gossamer Bio, Inc. has a beta of 1.921, which suggesting that the stock is 92.071% more volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.919%.

Gossamer Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Gossamer Bio, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Gossamer Bio, Inc. quarterly revenues are $13.3M, which are larger than XOMA Royalty Corp. quarterly revenues of $9.4M. Gossamer Bio, Inc.'s net income of -$48.2M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Gossamer Bio, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 34.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Gossamer Bio, Inc. is 16.66x versus 9.06x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.